clinical trial · NCT06772597
A Study of Setmelanotide in Patients With Prader-Willi Syndrome
Prader-Willi SyndromeObesityHyperphagiaSetmelanotide
brief summary
This is a Phase 2, open-label study designed to assess the safety and efficacy of setmelanotide in patients with obesity due to Prader-Willi Syndrome (PWS) who are 6 to 65 years of age. Up to 20 patients are planned to be enrolled. Patients will take a daily subcutaneous dose of open-label setmelanotide for up to 52 weeks.
started
Mar 4, 2025
primary completion
Oct 31, 2026
completion
Oct 31, 2027
last updated
Feb 12, 2026
official title
A Phase 2 Open-label Study of Setmelanotide in Patients With Prader-Willi Syndrome
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol